News for RLFTF Stock

Relief Therapeutics Receives FDA Response to QIDP Request for RLF-TD011 Relief Therapeutics Announces Results of Annual General Meeting Relief Therapeutics Receives FDA Rare Pediatric Disease Designation for RLF-TD011 Relief Therapeutics Publishes 2025 Annual General Meeting Agenda Relief Therapeutics Reports 2024 Financial Results and Provides Corporate Update Relief Therapeutics Announces Conclusion of Merger Discussions with Renexxion Relief Therapeutics Announces European Patent Office Decision to Grant Patent for RLF-TD011 Relief Therapeutics Completes Strategic Transition with Sale of GOLIKE Rights ex-US Relief Therapeutics Provides Update on Potential Transaction with Renexxion Relief Therapeutics Announces Final Readout of PKU GOLIKE Clinical Trial Relief Therapeutics Announces Filing of Form 15F to Terminate SEC Reporting Obligations Relief Therapeutics Announces Positive Final Results of RLF-TD011 Clinical Trial in Epidermolysis Bullosa Relief Therapeutics Signs Non-Binding Letter of Intent with Renexxion for Reverse Merger Relief Therapeutics Announces Publication of Plain Language Summary on PKU GOLIKE Relief Therapeutics Reports New Study Results for RLF-OD032 and Files Provisional Patents Relief Therapeutics Receives Notice of Allowance for European Patent Covering RLF-TD011 for Epidermolysis Bullosa Wound Treatment Relief Therapeutics Announces Promising Preliminary Results of RLF-TD011 Clinical Trial in Epidermolysis Bullosa Relief Therapeutics Reports Positive Results from RLF-OD032 Proof-of-Concept Clinical Study for Phenylketonuria Relief Therapeutics Completes Clinical Phase in RLF-OD032 Proof-of-Concept Study; Topline Results Expected in October 2024 Relief Therapeutics Announces PKU GOLIKE Study Results Presentation at SSIEM 2024 Relief Therapeutics Reports Half-Year 2024 Financial Results and Provides Corporate Update Relief Therapeutics Secures up to $11 Million from Royalty Sales RELIEF THERAPEUTICS Holding SA Announces Results of Annual General Meeting Relief Therapeutics Announces Executive Changes Relief Therapeutics Announces Notice of Annual General Meeting of Shareholders Relief Therapeutics Announces New Executive Leadership Team Strengthening Capabilities to Guide the Company through Pipeline Development Initiatives Relief Therapeutics has Published its Annual Report RELIEF THERAPEUTICS Holding SA Announces Results of Extraordinary General Meeting RELIEF THERAPEUTICS Holding SA to Hold Extraordinary General Meeting Relief Therapeutics Enters into Exclusive U.S. License and Supply Agreement with Eton Pharmaceuticals for PKU GOLIKE Relief Therapeutics Renews CHF 50 million Share Subscription Facility Relief Therapeutics Shifts Commercial Operations to Partnership Model, Focusing on Efficient Patient Access and R&D Growth Relief Therapeutics Announces CEO Transition Relief Therapeutics Announces that more than 400,000 of its ADRs are Currently Outstanding and that, as a Result, the Company has Achieved an Important NASDAQ Initial Listing Milestone Relief Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference Relief Therapeutics Announces Extension of Distribution Agreement for PKU GOLIKE(R) in the U.S. with Pentec Health Relief Therapeutics Announces Swissmedic Approval and Operation of New Good Manufacturing Practice-Compliant Laboratory Relief Therapeutics Has Filed its 2022 Annual Report on Form 20-F with the U.S. Securities and Exchange Commission Relief Therapeutics Announces Implementation Timeline for Reverse Split of Ordinary Shares Relief Therapeutics Announces Collaboration Partner Reports OLPRUVA(TM) Commercial Launch Progressing Ahead of Schedule Relief Therapeutics Announces Results of Extraordinary General Meeting of Shareholders Relief Therapeutics Announces Positive 12-Month Stability Data for Inhaled and Intravenous Preparations of RLF-100 Relief Therapeutics Announces Full Year 2022 Financial Results and Provides Corporate Update Relief Therapeutics Announces Executive Leadership Team Change Relief Therapeutics Holding SA to Hold Extraordinary General Meeting of Shareholders Relief Therapeutics Appoints World-Renowned Gene Therapy Pioneer Guangping Gao, Ph.D. as Chair of Scientific Advisory Board Relief Therapeutics Announces Survey Results Identifying Preferred Urea Cycle Disorder Treatment Attributes Presented by Collaboration Partner at SIMD 2023 Relief Therapeutics to Present Pre-Clinical Evidence for Improved Amino Acid Utilization with PKU GOLIKE at the Society for Inherited Metabolic Disorders 44th Annual Meeting Relief Therapeutics Announces Availability of New PKU GOLIKE BARs in Europe Relief Therapeutics Provides Update From Collaboration Partner on OLPRUVA Relief Therapeutics Recognizes Rare Disease Day and Announces U.S. Availability of New PKU GOLIKE Bars Relief Therapeutics Announces Enrollment of First Three Patients in Proof-of-Concept Clinical Trial of RLF-TD011 for the Treatment of Epidermolysis Bullosa Relief Therapeutics Provides an Update on its Financing Strategy Relief Therapeutics Announces IRB Approval of Investigator-Initiated Trial Evaluating RLF-TD011 as an Adjunctive Treatment for Cutaneous T-Cell Lymphom Relief Therapeutics Files Amendment No. 2 to its Registration Statement on Form F-1 with the U.S. Securities and Exchange Commission Relief Therapeutics Holding SA and NRx Pharmaceuticals, Inc. Announce Close of Definitive Settlement Agreements Relief Therapeutics to Participate in January Investor Meetings Relief Therapeutics Announces Issuance of Shares from Authorized Capital Relief Therapeutics Announces Executive Leadership Team Changes Relief Therapeutics Files Amendment No. 1 to its Registration Statement on Form F-1 with the U.S. Securities and Exchange Commission Relief Therapeutics Holding SA and NRx Pharmaceuticals, Inc. Announce Execution of Definitive Settlement Agreements Relief Therapeutics Holding SA and NRx Pharmaceuticals, inc. Further Extend their Stay of Pending Litigation to Provide Additional Time for the Parties to Finalize their Litigation Settlement Relief Therapeutics Announces Six-Month Stability Data on a New Formulation of RLF-100 (Aviptadil) RELIEF THERAPEUTICS Holding SA and NRx Pharmaceuticals, Inc. Extend Their Stay of Pending Litigation to Provide Additional Time for The Parties to Finalize Their Settlement Relief Therapeutics Files Amendment No. 2 to its Form F-6 Registration Statement with the U.S. Securities and Exchange Commission Relief Therapeutics Announces Promotion of Paolo Galfetti to Chief Operating Officer Relief Announces U.S. Launch of PKU GOLIKE Relief Announces Exclusive Distributor for PKU GOLIKE in the U.S. Relief Therapeutics Announces IRB Approval and Initiation of an Investigator Initiated Trial of Nexodyn for Epidermolysis Bullosa at Ann & Robert H. Lurie Children's Hospital of Chicago Relief Reports Half-Year 2022 Results and Provides Corporate Update Relief Therapeutics to Participate in the 22nd Annual Biotech in Europe Forum Relief Therapeutics to Participate in the H.C. Wainwright 24th Annual Global Investment Conference Relief Therapeutics Files Registration Statement on form F-1 with the U.S. Securities and Exchange Commission Relief Therapeutics Holding SA and NRx Pharmaceuticals, Inc. Announce Tentative Settlement of Pending Litigation Relief Therapeutics Appoints David McCullough as Head of U.S. Market Access Relief Therapeutics Announces Promising Initial Stability Data on a New Formulation of RLF-100(R) (Aviptadil) Relief Therapeutics Announces Effectiveness of Registration Statement on Form 20-F Relief Therapeutics Announces that its Collaboration Partner has Resubmitted the ACER-001 (Sodium Phenylbutyrate) New Drug Application (NDA) to the FDA for the Treatment of Urea Cycle Disorders (UCDs) Relief Therapeutics Appoints Serene Forte, Ph.D., MPH, as Senior Vice President, Head of Genetic Medicine Relief Signs a Definitive Agreement to Acquire a Novel Dosage Form of an Already Approved Prescription Drug for the Treatment of PKU Relief Therapeutics Files Amendment No. 4 to its Registration Statement on Form 20-F with the U.S. Securities and Exchange Commission Relief Reports that its U.S. Collaboration Partner has Announced that the FDA has Declined Emergency Use Authorization for Aviptadil for a Subgroup of Patients with Critical COVID-19 at Immediate Risk Relief Therapeutics Files Amendment No. 3 to its Registration Statement on Form 20-F with the U.S. Securities and Exchange Commission Relief Reports that its U.S. Collaboration Partner has Announced an Update on Breakthrough Designation for Aviptadil Relief Reports that its Collaboration Partner, Acer Therapeutics, Issued a Statement Regarding the PDUFA Target Action Date for ACER-001 Relief Therapeutics Announces Results of Annual General Meeting of RELIEF THERAPEUTICS Holding SA Relief Provides a Corporate Update and Comments on the Recently Announced DSMB Update on the U.S. National Institutes of Health (NIH) Study of Intravenous Aviptadil in Critical COVID-19 Patients Relief Reports that its U.S. Collaboration Partner Announces Data Safety Monitoring Board (DSMB) Update on the U.S. National Institutes of Health (NIH) Study of aviptadil in Critical COVID-19 Relief Therapeutics Expands U.S. Commercial Team Relief Therapeutics Files Amendment No. 2 to its Registration Statement on Form 20-F with the U.S. Securities and Exchange Commission Relief Therapeutics to Participate in Industry and Investor Conferences in May Acer Therapeutics and Relief Therapeutics Announce Presentation of ACER-001 Data at the Genetic Metabolic Dieticians International Conference Relief Therapeutics Announces Notice of Annual General Meeting of RELIEF THERAPEUTICS Holding SA Relief Therapeutics' Wholly Owned Subsidiary, APR Applied Pharma Research, Receives Notice of Allowance of Key U.S. Patent Application Covering PKU GOLIKE(R) Relief Therapeutics Appoints Drew Cronin-Fine as Executive Director, Head of U.S. Marketing Relief Reports that its U.S. Collaboration Partner has Filed a New Breakthrough Therapy Designation Request for Aviptadil Acer Therapeutics and Relief Therapeutics Announce Presentation of ACER-001 Data at the Society for Inherited Metabolic Disorders Annual Meeting Relief Therapeutics Announces that its Subsidiary was Issued a Swiss Patent Entitled 'Vasoactive Intestinal Peptide (VIP) for the Use in the Treatment of Drug-induced Pneumonitis' Relief Reports that its U.S. Collaboration Partner has Announced that the I-SPY COVID Trial Suggests No Clinical Benefit with Addition of Nebulized Aviptadil in Critically Ill Patients with COVID-19 Relief Reports Full-Year 2021 Results and Provides Corporate Update Relief Therapeutics Reports In Vivo Data Indicating Prolonged Release of Amino Acids Using its Physiomimic(TM) Technology May Have Benefits for the Treatment of PKU Relief Receives Trademark Registration for RLF-100(R) From the U.S. Patent and Trademark Office Relief Therapeutics Appoints Christopher Wick as Senior Director, Head of U.S. Sales Relief Therapeutics Files Amendment No. 1 to its Registration Statement on Form 20-F with the U.S. Securities and Exchange Commission Relief Therapeutics' Wholly Owned Subsidiary, APR Applied Pharma Research, Reports Final Data from Its Clinical Trial of Novel Nasal Spray, Sentinox, in SARS-CoV-2 Infected Patients Relief Therapeutics' Wholly Owned Subsidiary, APR Applied Pharma Research Signs an Agreement To Acquire Rights to Commercialize a Novel Dosage Form for the Treatment of PKU Relief Reports that its U.S. Collaboration Partner has Announced that the U.S. National Institutes of Health Study of Aviptadil in Critical COVID-19 is Cleared to Complete Full Enrollment Relief Files Trademark Application for RLF-100 With the U.S. Patent and Trademark Office Relief Therapeutics Expands Its Board of Directors with the Appointment of Michelle Lock Relief Announces That Collaboration Partner, Acer Therapeutics, was Issued U.S. Patent 11,202,767 Covering ACER-001 Methods of Use for Treatment of Urea Cycle Disorders and Maple Syrup Urine Disease Relief Therapeutics Announces Results of Extraordinary General Meeting of RELIEF THERAPEUTICS Holding SA Relief Reports that its U.S. Collaboration Partner has Announced Receipt of Initial Report of Patient Safety and Survival from Right to Try Use of Aviptadil During Omicron Surge Relief Therapeutics' Wholly Owned Subsidiary, APR Applied Pharma Research, Receives Notice of Allowance of Key U.S. Patent Application Covering Ready to Use Diclofenac Stick Packs Relief Reports US Collaboration Partner Announces Expansion of Aviptadil US Expanded Access & Right to Try Programs for Patients w/COVID-19 Respiratory Failure who've Exhausted All Approved Therapies Relief Therapeutics Comments on NRx Pharmaceuticals' Press Release Reporting on its Recently Filed Lawsuit Relief Comments on Lawsuit Filed Against It by NeuroRx Relief Reports US Collab. Partner Announces Submission to FDA seeking EUA for Aviptadil for Pts at Immediate Risk of Death from COVID-19 Despite Treatment w/Remdesivir, Other Approved Therapies Relief Therapeutics to Participate in Virtual Investor Conferences in January Relief Reports that its U.S. Collaboration Partner has Announced the Filing of a Provisional Patent Application for Stable Compositions of Aviptadil Suitable for Human Use Relief Therapeutics Announces Notice of Extraordinary General Meeting of RELIEF THERAPEUTICS Holding SA Relief Reports U.S. Collab. Partner Announces Filing Breakthrough Therapy Request for Aviptadil in Pts at Immediate Risk of Death from COVID-19 Despite Treatment w/Remdesivir, Other Approved Therapies Relief Reports Successful Conclusion of Patent Examination Procedure for Patent Application Entitled, 'Vasoactive Intestinal Peptide (VIP) for the Use in the Treatment of Drug-induced Pneumonitis' Relief Therapeutics Files Registration Statement on Form 20-F with the U.S. Securities and Exchange Commission Relief Reports that U.S. Collaboration Partner Announces New, Favorable Safety Report for Aviptadil in NIH Sponsored ACTIV-3b Critical Care Study in Patients with Life-Threatening COVID-19 Relief Reports that its U.S. Collaboration Partner has Agreed with Hungarian Health Officials on a Pathway for Aviptadil Relief Therapeutics Announces Executive Changes Relief Reports U.S. Collaboration Partner Identifies Significantly Higher Likelihood of Surviving & Recovering from Critical COVID-19 in Aviptadil Treated Patients Previously Administered Remdesivir Relief Therapeutics and InveniAI Sign a Strategic Collaboration Agreement to Identify New Product Development Opportunities using Artificial Intelligence Relief Reports that its U.S. Collaboration Partner has Announced the U.S. Food and Drug Administration has Denied Breakthrough Designation for Aviptadil Relief Therapeutics Launches Level 1 ADR Program in the United States Relief Reports that its U.S. Collaboration Partner has Announced it has Received a U.S. Food and Drug Administration Review of Aviptadil Manufacturing Information Relief Provides Corporate Update and Outlines Plans to Advance its Diversified Portfolio of Pipeline Candidates, Including RLF-100(TM) (Aviptadil) Relief Therapeutics Announces Transitions in Commercial Organization to Implement Next Phase of Corporate Development Relief Reports U.S. Collaboration Partner's Emergency Use Authorization Request for ZYESAMI/RLF-100 (aviptadil) for Patients with Critical COVID-19 with Respiratory Failure was Declined by U.S. FDA Relief Therapeutics Takes First Step to Create an ADR Program in the United States by Filing a Form F-6 Registration Statement with the U.S. Securities and Exchange Commission Relief Reports U.S. Collaboration Partner has Announced Favorable New Safety Report for Aviptadil in NIH Sponsored ACTIV-3b Critical Care Study in Patients with Life-Threatening COVID-19 Relief Therapeutics' Wholly Owned Subsidiary, APR Applied Pharma Research, Reports Positive Interim Data from Its Clinical Trial of Novel Nasal Spray Sentinox in SARS-CoV-2 Infected Patients Relief Therapeutics Reports Two Publications of Positive Data on Nexodyn(R) AOS for Hard-to-Heal Ulcers Relief Reports U.S. Collaboration Partner Announces Journal of Infectious Diseases and Treatment Publishes Positive Aviptadil Data in High Comorbidity Critical COVID-19 Patients w/ Respiratory Failure Relief Reports that its U.S. Collaboration Partner has Announced Progress on Worldwide Commercial Scale Development of ZYESAMI(TM) (aviptadil) Relief Reports that U.S. Collaboration Partner Announced Second Favorable Safety Report for ZYESAMI(TM) (RLF-100TM/aviptadil) in NIH Sponsored ACTIV-3b Critical Care Study in Life-Threatening COVID-19 Relief's Subsidiary, APR Applied Pharma Research, Reports Data Published in Journal of Wound Care, Indicating Nexodyn(R) AOS Highly Effective Treatment to Support Healing of Hard-to-Heal Leg Ulcers Relief Reports that its U.S. Collaboration Partner has Announced Improved Survival at One Year in Highly Comorbid COVID-19 Patients Treated with ZYESAMITM (RLF-100TM/aviptadil) Relief Reports Half-Year 2021 Results and Provides Corporate Update Relief's Wholly Owned Subsidiary, APR Applied Pharma Research, Reports Data Published in Peer Reviewed Journal, Nutrients, Indicating Additional Potential Benefits of Its Physiomimic(TM) Technology Relief Therapeutics Provides Update on Regulatory Interactions in the United Kingdom and European Union Relating to Lead Drug Candidate, RLF-100 (Aviptadil) Relief Therapeutics' Wholly Owned Subsidiary, APR Applied Pharma Research, Launches PKU GOLIKE(R) KRUNCH in Germany and Italy Relief Therapeutics to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference Relief Therapeutics Comments on Certain Statements Made by NRx Pharmaceuticals in its Registration Statement on Form S-1 Filed on September 3, 2021 Relief Reports Regulatory Clearance in Germany to Commence a Multicenter, Double-blind, Randomized Phase 2 Clinical Trial to Evaluate Inhaled Aviptadil for the Treatment of Sarcoidosis Relief Reports that U.S. Collaboration Partner has Announced a New Finding from Aviptadil Phase 2b/3 Trial Demonstrating Clinically Significant Relief from Respiratory Distress in Critical COVID-19 Relief Reports that its U.S. Collaboration Partner has Announced a Positive Safety Report for ZYESAMI(TM) (aviptadil) in NIH Sponsored ACTIV-3 Study in Patients with Life-Threatening COVID-19 Relief Announces Receipt of U.S. FDA Orphan Drug Designation for the use of RLF-100 (aviptadil) in the Treatment of Sarcoidosis Relief Reports that its U.S. Collaboration Partner has Announced Emergency Use Authorization of Aviptadil in Nation of Georgia Relief and AdVita Close Definitive Agreement for Relief to Acquire All Outstanding Shares of AdVita Relief Therapeutics Announces CHF 15 Million Private Placement Relief Reports that its U.S. Collaboration Partner has Announced Successful Commercial Formulation for Aviptadil Relief Announces Issuance of Shares from Authorized Capital as Approved by 2021 Annual General Meeting Relief Reports that its U.S. Collaboration Partner has Presented Evidence that Aviptadil Helps to Prevent Cytokine Storm in Patients with COVID-19 Relief Therapeutics Reports that Collaboration Partner, NRx Pharmaceuticals, and Quantum Leap Announce Treatment of Severely Ill COVID-19 Patients with Aviptadil in the I-SPY COVID Trial NRx Pharmaceuticals Announces Initiation of Emergency Use Training and Extension of Phase 2/3 Inhaled ZYESAMI™ (Aviptadil-acetate) Trial in the Nation of Georgia Relief and APR Applied Pharma Research Sign and Close Definitive Agreement for Relief to Acquire All Outstanding Shares of APR Relief Announces the Results of the Annual General Meeting 2021 of RELIEF THERAPEUTICS Holding AG: All Proposals Approved by a Large Majority Relief Therapeutics Reports that Collaboration Partner, NRx Pharmaceuticals, has Announced Additional Results from the Aviptadil U.S. Expanded Access Protocol for Patients with Critical COVID-19 Relief Therapeutics Reports that its Collaboration Partner, NRx Pharmaceuticals, has Submitted an Application for Emergency Use Authorization for Aviptadil to the U.S. Food & Drug Administration NRx Pharmaceuticals Announces Positive Results for ZYESAMI™ (Aviptadil-acetate) and Submits Emergency Use Authorization Application to US Food and Drug Administration to Treat Critical COVID-19 in Patients Suffering from Respiratory Failure Relief Appoints Dr. Taneli Jouhikainen as Chief Operating Officer Relief Announces Notice of Annual General Meeting of RELIEF THERAPEUTICS Holding AG Relief Provides Update on Progress and Plans with ACER-001 for the Treatment of Urea Cycle Disorders Relief Points to Applied Pharma Research (APR) News re: Pivotal COVID-19 Trial Initiation with Novel Nasal Spray Relief and Applied Pharma Research (APR) Sign Binding Term Sheet for Relief to Acquire All Outstanding Shares of APR Relief and AdVita Announce Initiation of Phase 2 Trial with Inhaled RLF-100 for the Prevention of COVID-19-related Acute Respiratory Distress Syndrome Relief Comments on Certain Statements Made by NeuroRx, Inc. in the Amended Form S-4 Filing of Big Rock Partners Acquisition Corp. Relief Reports 2020 Financial Results and Provides Business Update Relief Engages Jan-Jaap Scherpbier of Sonsbeek Pharma Consultancy B.V. as Manufacturing and Supply Chain Consultant NeuroRx Announces ZYESAMI™ (aviptadil, RLF-100) Met the Primary Endpoint of Its Phase 2b/3 Clinical Trial and Also Demonstrated a Meaningful Benefit in Survival from Critical COVID-19 NeuroRx Announces that ZYESAMI™ (Aviptadil) has Successfully Demonstrated 10-Day Accelerated Recovery from Respiratory Failure in Critically Ill Patients with Covid-19 Treated with High Flow Nasal Oxygen at 28-Day Interim Endpoint NeuroRx and Relief Therapeutics Report Initial Phase 2b/3 Study Results Demonstrating Significant Benefit of ZYESAMI™ in Reducing Hospital Stay Among Patients with Respiratory Failure due to Critical COVID-19 NeuroRx submits request for Emergency Use Authorization for RLF-100™ (aviptadil) in the treatment of patients with Critical COVID-19 and Respiratory Failure who have exhausted approved therapy Relief Reports Half-Year 2020 Results Relief Appoints Gilles Della Corte, M.D. as Chief Medical Officer Relief Announces Successful Up-listing from OTC Pink to OTCQB and Capital Increase from its Share Subscription Facility with GEM Relief Reports that NeuroRx has Announced Feasibility Collaboration with TFF Pharmaceuticals Relief Announces CHF 10 Million Private Placement Relief Increases Issued Share Capital with Creation of Treasury Shares NeuroRx Announced that RLF-100(TM) has Demonstrated Ten-Day Accelerated Recovery from Respiratory Failure among Patients with Severe Covid-19 Treated with HFNO at 28 Day Interim Endpoint Relief Announces Resignation of Thomaz Burckhardt as Member of the Board of Directors Relief Affirms Initiation of Phase 2/3 Trial of Inhaled RLF-100(TM) (Aviptadil; ZYESAMI(TM)) in Severe COVID-19 Patients CORRECTION: NeuroRx and Relief Announce Initial Successful Results from Expanded Access Use of RLF-100(TM) (aviptadil) in Patients with Critical COVID-19 and Severe Comorbidity: 72% Survival Seen in ICU Patients Relief Announces Notice of Extraordinary General Meeting of RELIEF THERAPEUTICS Holding AG Relief, with Partner NeuroRx, Announces Enrollment of 150 Patients in Phase 2b/3 Trial of RLF-100(TM) for Critical COVID-19 with Respiratory Failure Relief Appoints J. Paul Waymack, M.D., Sc.D. as Consultant to Strengthen Management Team Relief Therapeutics Appoints Industry Veteran, Jack Weinstein, as Chief Financial Officer and Treasurer Relief Announces Capital Increase from its Final Tranche of the Share Subscription Facility with GEM